---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003119"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:22:50.136319+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Filana Therapeutics Q1 net loss $10.3M; cash $86.6M, clinical hold on TSC program remains

## Summary
- Net loss of $10.3M ($0.21 per share) vs $23.4M loss in Q1 2025.
- Cash and cash equivalents $86.6M at March 31, 2026; no debt.
- R&D expenses $4.5M, down 67% due to Alzheimer's program phase-out.
- Company still addressing FDA clinical hold for simufilam in TSC-related epilepsy.
- Preclinical data in Epilepsia showed simufilam attenuated seizure progression in TSC mouse model.

## SEC filing metadata
- accession: 0001171843-26-003119
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184326003119/0001171843-26-003119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184326003119/f8k_050726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003119
- JSON: https://secwatch.observer/filing/0001171843-26-003119.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003119.txt

## Source-grounded claims
- claim_id: 3916f6dd11a1ea650ce31ccfd5ae511926d195f0
  claim: FILANA THERAPEUTICS, INC. reported the first quarter ended March 31, 2026 results: net income $10.3 million, EPS $0.21 per share.
  evidence_excerpt: Net loss was $10.3 million, or $0.21 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000117184326003119/0001171843-26-003119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.